No Data
Is Shanghai Medicilon (SHSE:688202) Weighed On By Its Debt Load?
Medici: Medici: THIRD QUARTER REPORT 2024
Medici: Third quarter report 2024
shanghai medicilon inc. (688202.SH): net loss of 0.129 billion yuan in the first three quarters.
On October 30, shanghai medicilon inc. (688202.SH) announced that the company achieved revenue of 0.802 billion yuan in the first three quarters, a year-on-year decrease of 32.2%; net income attributable to the parent company was -0.129 billion yuan; non-recurring net profit attributable to the parent company was -0.142 billion yuan.
The Market Lifts Shanghai Medicilon Inc. (SHSE:688202) Shares 41% But It Can Do More
shanghai's three major leading industry mother funds have started, catalyzing CRO companies like shanghai medicilon inc. to embrace new opportunities for technological innovation.
Recently, Shanghai Guotou Leading Private Equity Fund Management Company officially launched the selection work for the sub-funds of the three leading industrial parent funds, aiming to enhance the development level of Shanghai's integrated circuits, biomedical, and ai industries, in order to promote the high-quality development of the Shanghai economy. As one of the economic centers of China, Shanghai, with biomedical as an important industry pillar, has nurtured many excellent research institutions and high-level pharmaceutical companies here. The scale of the Shanghai biomedical industry has grown from 103.46 billion yuan in 2008 to 600 billion yuan in 2020, with a compound annual growth rate of 15.8%.
Is Shanghai Medicilon (SHSE:688202) Using Too Much Debt?
No Data
No Data
